Development of a Structured Education Programme for Women With Polycystic Ovary Syndrome (SUCCESS)
|ClinicalTrials.gov Identifier: NCT01462864|
Recruitment Status : Completed
First Posted : November 1, 2011
Last Update Posted : May 30, 2017
Polycystic Ovary syndrome (PCOS) is a common hormonal imbalance affecting about 12% of women in the UK. The number of women with PCOS is rising. They suffer from a combination of symptoms including excess hair, irregular/absent periods, and infertility. About 70% of women with PCOS are obese or overweight, 10% develop type 2 diabetes (T2DM), and 30-40% have some degrees of abnormality in controlling (metabolising) blood sugar. Studies have shown that if women with PCOS make change to their lifestyle (diet and activity), they may reduce their risk of getting diabetes and heart disease in the future. This study aims to develop and test a programme that can be run in groups (structured education), to support women with PCOS make the lifestyle changes needed to improve their PCOS and prevent future associated health problems. Structured education programmes are suitable for use within the NHS and are already recommended for individuals with T2DM, but have not been tested as a method of treatment for PCOS which is a high risk condition for T2DM.
The investigators aim to initially develop a specific education programme for women with PCOS using their expertise in their disease and defining their needs. The next step is to test this programme on 160 women with PCOS who will be selected from the investigators database or clinics. They will be divided randomly to two groups to receive either this programme or routine care.
The investigators will give them an accelerometer (a very small portable device). This will measure their physical activity and counts their daily steps. The investigators aim is to increase their step count by at least 2000 steps per day after one year.
The investigators believe that the group given the structured education will show some evidence of improvement in their glucose metabolism, and consequently decreased chance of developing diabetes.
|Condition or disease||Intervention/treatment|
|Polycystic Ovary Syndrome||Behavioral: Structured Lifestyle Education|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||162 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||StructUred eduCation Programme to Improve Cardiovascular Risk in womEn With polycyStic Ovary Syndrome; SUCCESS Study|
|Study Start Date :||September 2011|
|Primary Completion Date :||December 2014|
|Study Completion Date :||December 2014|
Active Comparator: Intervention
Lifestyle education intervention
Behavioral: Structured Lifestyle Education
A 3-4 hours group education delivered in a patient group composed of 4-8 patients and delivered by two healthcare professionals.
No Intervention: Control
The control group will receive an information leaflet which is generally distributed in our speciality clinic to patients with diagnosis of PCOS. The leaflet includes general information on PCOS, treatment options and advice on increasing physical activity.
- we aim for a 2000 steps increase in Number of steps per day [ Time Frame: One year ]It has been shown that 1 mmol/L drop in 2 hours glucose tolerance test following lifestyle intervention is significantly effective in diabetes prevention equal to 50% reduction in progression to T2DM. A previous similar intervention in people with IGR by our group in Leicester achieved a significant drop of 1.31 mmol/L (SD 2 mmol/L) in 2 hours glucose tolerance through an increase of 2000 steps per day in walking activity (SD 4000 steps/day).
- Physical Activity [ Time Frame: One year ]Physical activity will be objectively measured using the accelerometer and also IPAQ.
- Biochemical variables [ Time Frame: One year ]
- Oral glucose tolerance test
- Blood lipid profile, liver and Kidney function test, albumin, vitamin D, calcium and full blood count.
- Hormonal assay; Follicular Stimulating Hormone (FSH), Luteinizing Hormone (LH), Testosterone, Sex Hormone Binding Globulin (SHBG), Dehydroepiandostrone (DHEAS), and Androstendione. Day 21 Progesterone level (unless on ovulation suppression medication).
- Insulin, HbA1c, HOMA-B, HOMA-IR
- hsCRP, TNF alpha, IL-6, and sIL-6R, fibrinogen, adiponectin
- Anthropometric and demographic [ Time Frame: One year ]
- Blood pressure
- Body weight
- Body fat percentage
- Health Related Quality of Life [ Time Frame: One Year ]PCOSQ is the only specified health related quality of life questionnaire developed and tested for this condition (Cronin 1998), which has been validated in UK (Jones 2004). It contains 26 items measuring 5 areas; emotions, body hair, weight, infertility problems, and menstrual problems.
- Exercise and Barrier Self Efficacy [ Time Frame: One Year ]It will be measured using the 100% confidence rating scale (from 0% = no confidence to 100% = complete confidence) (Keller 1999). This self-efficacy questionnaire measures participants' confidence in their ability to undertake any form of moderate- to vigorous-intensity physical activity for 10 minute periods, increasing incrementally from 10 minutes to one hour each day. An overall score is calculated by summing the efficacy scores for each time period and dividing by the number of time periods.
- Epworth Sleepiness Scale [ Time Frame: One Year ]The risk of Obstructive Sleep Apnoea (OSA) has been reported to be 5 to even 30 fold higher in women with PCOS (Nitsche 2010). Epworth Sleepiness Scale is the standard questionnaire developed for clinical assessment of behavioural morbidity associated with OSA and can assess the degree of sleepiness reliably as an screening tool. (Doghramii 2008).
- Body Fat Composition [ Time Frame: One Year ]In a sub-study of the SUCCESS study population, a whole body dual energy X-ray absorptiometry (DEXA) scan and a single section abdominal magnetic resonance imaging (MRI) scan taken in the L3-L4 region will be used to measure soft tissue body composition and visceral and subcutaneous abdominal fat distribution respectively.
- Brief Illness Perception [ Time Frame: One Year ]This nine item validated instrument uses an 11 point Likert scale (0 = no effect, 10 = complete effect) to measure five cognitive illness representations (consequences, timeline, personal control, treatment control, and identity), two emotional representations (concern and emotion) and illness comprehensibility (perceived knowledge). The BIPQ has been shown to have reasonable test-retest reliability and concurrent validity (Broadbent 2006).
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01462864
|University Hospitals of Licester|
|Leicester, Leicestershire, United Kingdom, LE1 5WW|
|Principal Investigator:||Melanie J Davies, Prof (MD)||University of Leicester|
|Study Chair:||Kamlesh Khunti, Prof (PhD)||University of Leicester|
|Study Director:||Hamidreza Mani, MD||University of Leicester|